Leftover immunotherapy may boost chemo: new study investigates timing

NCT ID NCT07633613

Not yet recruiting Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pembrolizumab and are starting chemo. By analyzing blood samples and tumor responses, they hope to find the best timing for switching treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab
What this could lead to: If successful, this could help doctors better time chemotherapy after immunotherapy to improve treatment outcomes for lung and head & neck cancers.
What could go wrong: This is an early-stage observational study, not a treatment trial. It may not lead to any change in practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA NON SMALL CELL LUNG CARCINOMA NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.